Eldecalcitol
Eldecalcitol has been studied in 20 papers since 2017: 5 trials and 3 observational studies in people, 8 in animals, 4 reviews; 10 in the past year. The newest paper, Oct 21, 2026: “Clinical investigation of effects of eldecalcitol on lipid profile and other metabolic parameters in osteoporosis-treatment-naïve postmenopausal women with osteoporosis”.
1 new paper in 30 daysSee all 25 papers on eldecalcitol
At a glance
The findings reach people, from one lab or study. 8 independent labs in 2 countries; 6 trials, 1 about aging, 2 with no results posted.
“3-year BMD increases were progressively greater with more favorable glycemic trajectories”
None of its findings points the other way.
- 8 independent labs in 2 countries
- 6 trials, 1 about aging, 2 with no results posted
- Funders: National Natural Science Foundation of China and others
- 3 of 34 findings with company ties
- 1 of 6 trials sponsored by its developers
- Human trial5
- Humans3
- Animals8
Studies in people
5 studies gave eldecalcitol to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
| Trial24 weeks | 54 peopleWomenPostmenopausal women; osteoporosis-treatment-naïve postmenopausal women with osteoporosis | Drug discoveries & therapeutics, Oct 21, 2026 | |
up: Improves lumbar spine bone mineral density4.6% in progression, 7.3% in persistent, 9.2% in regression | Treated cohort3 years | 1,164 peopleIn participants with prediabetes receiving eldecalcitol | The Journal of clinical endocrinology and metabolism, Sep 29, 2026 |
up: Increases skeletal muscle mass1.9 % vs. -3.4 % change, eldecalcitol vs placebo up: Increases muscle strength4.1 % vs. -0.7 % change, eldecalcitol vs placebo down: Decreases fat mass-3.2 % vs. 1.8 % change, eldecalcitol vs placebo | Randomized trial1 year | 32 people | Metabolism: clinical and experimental, Mar 28, 2025 |
down: Lowers the risk of sarcopeniaHR 0.51, 95% CI 0.31 to 0.83 no change: Has no effect on adverse events | Randomized trialmedian 2·9 years | 1,094 peopleBothmean age 60·8 yearsOlder adults; prediabetes | The lancet. Healthy longevity, Mar 1, 2024 |
up: Increases quadriceps muscle strength no change: Has no effect on balance and walking abilities no change: Has no effect on falls | Randomized trial6 months | 226 peopleWomenpostmenopausalPostmenopausal women; postmenopausal women with osteoporosis | Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, Mar 3, 2020 |
What did studies of eldecalcitol find?
30Studies of eldecalcitol measured 30 outcomes; the most studied are cellular senescence (4 studies) and bone loss (2).
Cellular senescence
downin rat cells2downin cells1downin mouse cells1
4 studies
Cellular senescence
downin rat cells2downin cells1downin mouse cells1
Eldecalcitol inhibits cellular senescence in dexamethasone-treated type H vascular endothelial cells.
“inhibiting vascular endothelial cells (ECs) senescence and improving angiogenesis and osteogenesis.”
Cellsin dexamethasone-treated type H vascular endothelial cells
Cellular signalling
Eldecalcitol inhibits cellular senescence in H2O2-treated macrophages.
“ED-71 effectively reduced cellular senescence-related indicators such as p16, p53 and β-galactosidase in macrophages”
Cellsin H2O2-treated macrophages
Bone
Eldecalcitol decreases cellular senescence in H2O2-treated osteoblasts.
“The combined effects of these two factors synergistically contribute to the improvement in osteoblast senescence.”
Cellsin H2O2-treated osteoblasts
Cellular signalling
Eldecalcitol decreases cellular senescence in bone mesenchymal stem cells from ovariectomized rats.
“ED-71 significantly improved the bone mesenchymal stem cells senescence caused by ovariectomized.”
Cellsin bone mesenchymal stem cells from ovariectomized ratsbone mesenchymal stem cell
Frontiers in pharmacology
Bone loss
downin animals1downin rats1
2 studies
Bone loss
downin animals1downin rats1
Eldecalcitol prevents bone loss in dexamethasone-induced osteoporosis.
“ED-71 prevents glucocorticoid-induced bone loss”
Animalsin dexamethasone-induced osteoporosis
Cellular signalling
Eldecalcitol prevents bone loss in ovariectomized rats.
“ED-71 prevented bone loss and inhibited weight gain in ovariectomized rats.”
Animalsin ovariectomized ratsbone30 ng/kg
Frontiers in pharmacology
Bone mineral density T-score
upin humans1
1 study
Bone mineral density T-score
upin humans1
Eldecalcitol increases bone mineral density T-score in humans (osteoporosis-treatment-naïve postmenopausal women with osteoporosis).
“T-scores (lumbar spine and femoral neck) significantly improved from baseline to 24 weeks after eldecalcitol administration (each P < 0.001).”
Human trialosteoporosis-treatment-naïve postmenopausal women with osteoporosislumbar spine and femoral neck0.75 μg per day24 weeksfemalesn = 54
Drug discoveries & therapeutics
Lumbar spine bone mineral density
upin humans1
1 study
Lumbar spine bone mineral density
upin humans1
Eldecalcitol improves lumbar spine bone mineral density in participants with prediabetes receiving eldecalcitol (4.6% in progression, 7.3% in persistent, 9.2% in regression).
“3-year BMD increases were progressively greater with more favorable glycemic trajectories”
Human trialin participants with prediabetes receiving eldecalcitol3 years
The Journal of clinical endocrinology and metabolism
Femoral neck bone mineral density
upin humans1
1 study
Femoral neck bone mineral density
upin humans1
Eldecalcitol is linked with higher femoral neck bone mineral density in humans.
“eldecalcitol co-therapy was independently associated with femoral neck BMD response”
Humans1 yearfemales
Medicina (Kaunas, Lithuania)
Postmenopausal osteoporosis
downin rats1
1 study
Postmenopausal osteoporosis
downin rats1
Eldecalcitol protects against postmenopausal osteoporosis in ovariectomized rats.
“Potential modulation of ED-71 in regulating H3K18 histone lactylation to suppress osteoclast differentiation and alleviate postmenopausal osteoporosis”
Animalsin ovariectomized rats
Biochemical pharmacology
Osteoclast differentiation
downin rats1
1 study
Osteoclast differentiation
downin rats1
Eldecalcitol inhibits osteoclast differentiation in ovariectomized rats and in vitro osteoclasts.
“ED-71 treatment effectively disrupts this regulatory axis by suppressing glycolysis, reducing H3K18la levels, and alleviating ER stress, inhibiting SOCE and restoring bone homeostasis.”
Animalsin ovariectomized rats and in vitro osteoclasts
Biochemical pharmacology
Mitochondrial calcium overload
downin cells1
1 study
Mitochondrial calcium overload
downin cells1
Eldecalcitol decreases mitochondrial calcium overload in dexamethasone-treated cells.
“reduces MAM-mediated mitochondrial calcium overload, inhibits senescence of ECs”
Cellsin dexamethasone-treated cells
Cellular signalling
Bone mass
upin mice1
1 study
Bone mass
upin mice1
Eldecalcitol improves bone mass in OVX mice.
“ED-71 improved bone mass and aging in OVX mice”
Animalsin OVX mice
Bone
Osteogenic differentiation
upin mouse cells1
1 study
Osteogenic differentiation
upin mouse cells1
Eldecalcitol improves osteogenic differentiation in indirect co-culture system with senescent macrophages.
“senescent macrophages impaired BMSCs osteogenic differentiation, an effect reversed by ED-71”
Cellsin indirect co-culture system with senescent macrophages
Bone
FOXO1 signaling
upin humans1
1 study
FOXO1 signaling
upin humans1
Eldecalcitol increases FOXO1 signaling in humans (versus placebo).
“eldecalcitol treatment for 1 year resulted in higher phosphorylation levels of mTOR and FOXO1 signaling pathways”
Human trialversus placeboskeletal muscle1 year
Metabolism: clinical and experimental
mTOR signaling
upin humans1
1 study
mTOR signaling
upin humans1
Eldecalcitol activates mTOR signaling in humans (versus placebo).
“eldecalcitol treatment for 1 year resulted in higher phosphorylation levels of mTOR and FOXO1 signaling pathways”
Human trialversus placeboskeletal muscle1 year
Metabolism: clinical and experimental
Fat mass
downin humans1
1 study
Fat mass
downin humans1
Eldecalcitol decreases fat mass in humans (versus placebo) (-3.2 % vs. 1.8 % change, eldecalcitol vs placebo).
“and lower fat mass (-3.2 % vs. 1.8 %, p = 1.73E-12)”
Human trialversus placebo1 yearn = 32
Metabolism: clinical and experimental
Muscle strength
upin humans1
1 study
Muscle strength
upin humans1
Eldecalcitol increases muscle strength in humans (versus placebo) (4.1 % vs. -0.7 % change, eldecalcitol vs placebo).
“and muscle strength (4.1 % vs. -0.7 %, p = 2.57E-17)”
Human trialversus placebo1 yearn = 32
Metabolism: clinical and experimental
Skeletal muscle mass
upin humans1
1 study
Skeletal muscle mass
upin humans1
Eldecalcitol increases skeletal muscle mass in humans (versus placebo) (1.9 % vs. -3.4 % change, eldecalcitol vs placebo).
“the eldecalcitol group had significantly higher skeletal muscle mass (1.9 % vs. -3.4 %, p = 3.26E-9)”
Human trialversus placeboskeletal muscle1 yearn = 32
Metabolism: clinical and experimental
All 30Fewer
What is eldecalcitol linked with?
1Studies link eldecalcitol with sarcopenia.
Sarcopenia
downin humans1HR 0.51
1 study
Sarcopenia
downin humans1HR 0.51
Eldecalcitol lowers the risk of sarcopenia in humans (prediabetes) (HR 0.51, 95% CI 0.31 to 0.83).
“Eldecalcitol treatment as compared with placebo showed statistically significant preventive effect on sarcopenia incidence”
Human trialprediabetes0·75 μg per daymedian 2·9 yearsn = 1,094
The lancet. Healthy longevity
Has eldecalcitol been tested in people?
1 of 6 about agingYes: 5 trials and 3 observational studies in people have been published, and 5 trials are registered.
About aging
Phase 4Recruiting
Every condition in trials
Phase 4Status unknown2 trials
Phase 4Status unknown2 trials
Osteoporosis in Postmenopausal Women
Phase 4Completed1 trial
Phase 4Status unknown1 trial
Phase 4Status unknown1 trial
Phase 4Recruiting1 trial
Trial sponsors
Zhejiang Provincial People's Hospital
1 trialPhase 4450 people
Chinese SLE Treatment And Research Group
1 trialPhase 4314 people
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
1 trialPhase 4300 people
Shanghai Jiao Tong University School of Medicine
1 trialPhase 4300 people
1 trialPhase 4100 people
1 trialPhase 1100 people